Tirzepatide denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tirzepatide as Not Medically Necessary

A medical-necessity denial from Aetna means the plan reviewed the clinical information submitted with your prior authorization request and concluded that the documentation did not sufficiently establish that tirzepatide is required for your condition given your individual clinical circumstances. This is one of the most common denial types and one of the most frequently overturned on appeal, because it is almost always a documentation gap rather than a genuine clinical disagreement.

Aetna's medical-necessity criteria for tirzepatide typically require confirmation of a specific qualifying diagnosis, evidence that clinically appropriate alternative therapies were tried and failed or are contraindicated per your prescriber's clinical judgment, and documentation of clinical severity. If any of these elements was absent or insufficiently detailed in the original submission, a well-documented appeal has a strong basis.

## Your Appeal Rights

• ACA §2719 / ERISA §503: Non-grandfathered group and individual-market plans must offer a full-and-fair internal review and independent external review.
• Internal appeal deadline: Generally 180 days from the denial; confirm on your Explanation of Benefits.
• External review window: If internal review fails, you typically have approximately four months to file for external review by an independent organization.
• Expedited option: For urgent situations, request expedited review in your appeal letter; decisions are required within a shorter federal timeframe.

## Documentation to Gather

1. Diagnosis confirmation: Current chart documentation — including recent visit notes and any relevant diagnostic results — clearly stating your diagnosis and its severity. 2. Prior treatment history with dates and outcomes: A written chronology of every prior therapy attempted, how long each was used, and the specific clinical reason it was discontinued (e.g., inadequate response, side effects documented in the chart). 3. Clinical severity per the chart: Objective measures recorded in your medical record that reflect your current condition severity. Your prescriber should reference these explicitly in the appeal narrative. 4. Prescriber medical-necessity letter: A detailed letter — ideally more than a form letter — that connects your clinical findings to each of Aetna's stated coverage criteria, explains why tirzepatide is the appropriate next step, and addresses why continuing or adding other agents would be clinically insufficient. 5. Insurer policy mapping: Obtain Aetna's current published clinical policy for tirzepatide. List every criterion and show, with a specific chart citation, how your case satisfies each one.

## Criteria-Mapping Structure

The most effective medical-necessity appeals use a structured format: Aetna's criterion (verbatim from policy) | Your chart evidence | Page/date of supporting document. Reviewers can then confirm compliance without having to search. Your prescriber's letter should be written to address each criterion in the same order they appear in the policy.

Review the FDA-approved prescribing information for tirzepatide and Aetna's most current published clinical policy before finalizing your appeal — criteria change, and you want to address the version currently in effect.